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Purpose. Depression and antidepressant use may independently increase the risk of acute myocardial infarction and mortality in
adults.However,nostudieshavelookedattheeﬀectofdepressiononabroaderthromboticeventoutcome,assessedantidepressant
use, or evaluated elderly adults. Methods. A cohort of 7,051 community-dwelling elderly beneﬁciaries who experienced a
thrombotic cardiovascular event (TCE) were pooled from the 1997 to 2002 Medicare Current Beneﬁciary Survey and followed
for 12 months. Baseline characteristics, antidepressant utilization, and death were ascertained from the survey, while indexed TCE,
recurrent TCE, and depression (within 6 months of indexed TCE) were taken from ICD-9 codes on Medicare claims. Time to
death and ﬁrst recurrent TCE were assessed using descriptive and multivariate statistics. Results. Of the elders with a depression
claim, 71.6% had a recurrent TCE and 4.7% died within 12 months of their indexed TCE, compared to 67.6% and 3.9% of those
elders without a depression claim. Of the antidepressant users, 72.6% experienced a recurrent TCE and 3.9% died, compared to
73.7% and 4.6% in the subset of selective serotonin reuptake inhibitor (SSRI) users. Depression was associated with a shorter time
to death (P = .008) in the unadjusted analysis. However, all adjusted comparisons revealed no eﬀect by depression, antidepressant
use, or SSRI use. Conclusions. Depression was not associated with time to death or recurrent TCEs in this study. Antidepressant
use, including measures of any antidepressant use and SSRI use, was not associated with shorter time to death or recurrent TCE.
Copyright © 2009 Christopher M. Blanchette et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Depression aﬀects one out of every three elders [1, 2]a n d
is associated with substantial societal and medical costs [2–
4]. Depressions leads to reductions in functional status and
productivity [5] and increases the risk of comorbidity [5]
and cardiac mortality [6]. Thrombotic cardiovascular events
(TCE) may play a key role in the etiology of depression and
subsequentmorbidityandmortalityduetofactorsassociated
with the event, including decreased functional status, social
isolation, comorbid chronic medical conditions, a sense
of death, and physiological processes [7–9]. It is unclear
whether pharmacological treatment for depression decreases
the risk of future cardiac complications.
1.1. Depression and Cardiac Events. F e ws t u d i e sh a v em e a -
sured the eﬀect of depression on recurrent cardiac events
following a TCE. Only one study in the elderly emerged. A
study of Japanese elders stratiﬁed by depression and followed
for 12 months found the annualized cardiac event rate to be
7.3% higher in depressed elders compared to nondepressed
elders [10]. Only one similar study was found in nonelders
[11].2 Cardiology Research and Practice
1.2. Depression and Cardiac Mortality. Depression in elders
leads to higher rates of cardiac mortality compared to non-
depressed elders. Although most studies do not diﬀerentiate
between elders and adults, there are some studies that
speciﬁcally assess cardiac mortality in elders with depression
after a TCE. Bush et al. found that depressed elders with left
ventricular ejection fraction <35% after an AMI had a 4-
monthmortalityrateof50%,comparedtothe12%mortality
rate of similar patients without depression [12]. Welin et al.
found that elders with higher scores on the BDI (indicating
more severe depression), who had experienced an AMI had
a threefold risk of coronary death compared to elders with
lower scores [13]. Findings were similar in the general adult
population. A study of post-AMI depressed individuals were
at a signiﬁcantly greater risk of cardiac mortality than post-
AMI nondepressed individuals at 6 months [6], 12 months
[14], 18 months [11, 15] and up to 27 years after initial
depression measurement [16].
Although a substantial amount of evidence has impli-
cated depression after a TCE as a risk factor for mortality,
two studies found that depression was not associated with
mortality [17, 18].
1.3. Antidepressant Treatment and Cardiac Events. Several
studies document the relationship between depression
treatment and morbidity and mortality. The Sertraline
Antidepressant Heart Attack Randomized Trial (SADHART)
indicated that rates of cardiovascular events were lower in
the sertraline (an SSRI) group than in the placebo group
(14.5% and 22.4%, resp.), which suggested the possible
protective eﬀect of SSRIs against recurrent cardiovascular
events, although the rates were not statistically diﬀerent
enough to be signiﬁcant [19]. Conﬂicting results were found
in observational studies, with some showing an increased
risk of AMI associated with tricyclic antidepressant use [20]
or SSRI antidepressant use within the ﬁrst 7 days [21]o r
if an SSRI is stopped within the month prior to the AMI
[22], and others demonstrating the protective nature of SSRI
antidepressants against AMI [22–24]. Still others have found
no eﬀect on AMI by tricyclic antidepressant use [24, 25],
SSRI antidepressant use [25], or other antidepressant use
[25]. The most important factor missing from all of these
studies is the inclusion of depression in the analyses. The
biologically based theories also suggest that a broader class
of thrombotic events may be related to depression and not
just AMI, as previous studies assess [26].
The purpose of this study was to examine whether
evidence of depression after a TCE places elders at a greater
risk of subsequent TCEs or mortality. This study also mea-
sures the eﬀect antidepressant treatment (and speciﬁcally
treatment with SSRIs) has on these outcomes. The analyses
are conducted in a high risk population of elderly Medicare
beneﬁciaries measuring outcomes within the ﬁrst twelve
months following an indexed TCE. The primary research
hypothesis is that a claim for depression is associated with
an increased risk of recurrent TCEs and mortality. The
secondary research hypothesis is that both antidepressant
and SSRI treatment for depression will also increase the risk
of recurrent TCEs and mortality.
2.MaterialsandMethods
2.1. Data. The Medicare Current Beneﬁciary Survey
(MCBS) is one of the richest databases available to study
disease and prescription drug use in the elderly. The MCBS
is a tri-annually administered survey linked to Medicare
Part A and B claims. It is designed and maintained by the
Centers for Medicare and Medicaid Services (CMS), the
federal agency responsible for the payment of services for
all Medicare and Medicaid beneﬁciaries. The design of
the MCBS is a longitudinal rotating panel, which includes
approximately 4000 long-term care (LTC) and community-
dwelling beneﬁciaries followed for three years. Each year
of the survey consists of three panels or approximately
12,000 Medicare beneﬁciaries. The survey contains
demographic characteristics, medical history, insurance
coverage, healthcare services use and expenditures, and
death. The MCBS is also one of the only available sources
of prescription drug use by Medicare beneﬁciaries. The
linkable claims ﬁles contain data on diagnosis, utilization,
and payment for inpatient and outpatient Medicare-covered
services. An attractive feature of the MCBS is the relatively
low loss to follow-up rate, only (8% to 10% annually) [27].
2.2. Sample Selection and Study Design. The design of the
study was a historical pooled cohort of 7,051 Medicare
beneﬁciaries aged 65 years of age and older residing in
the community who experienced a TCE according to the
deﬁnition of a thrombotic event set forth by Shaya et al. [28]
(AMI,ischemicheartdisease,acutepulmonaryheartdisease,
acute cerebrovascular diseases, or pulmonary and venous
embolisms). The cohort was pooled from elders residing
in the 1997 to 2002 MCBS. Elders were excluded from the
cohort if they: (1) were enrolled in a Medicare HMO (due
to nonavailable claims because of third-party handling); (2)
failed to complete one of the three surveys administered
annuallywithinatwoyearperiod(exceptwhenduetodeath)
in order to accurately observe antidepressant utilization; or
(3) resided in a long-term care facility during the baseline
year. Individuals in long-term care facilities lack prescription
drug utilization data in the MCBS, and in addition, the
etiology of their depression may be very diﬀerent than seen
with elders residing in the community. However, if the elder
transitionedtoanursingfacilityduringthefollow-upperiod,
the elder was included in the cohort provided that all other
inclusion criteria were met.
2.3.VariableMeasurement. Amonthlyanalyticﬁle(number-
ing 1 to 72 months across the study period, January 1997
through December 2002) was created in which elders were
noted as having had a TCE or depression in the month
corresponding to the date of service indicated on the claim
from one of three sources: inpatient, outpatient, or physician
oﬃcevisits.TheInternationalClassiﬁcationofDiseases,Ninth
Revision, (ICD-9) is the numerical system used to code any
written description of a diagnosis or medical condition.
For this study, the ICD-9 diagnostic codes listed on the
claims were used to identify depression and TCEs. TCEs
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of 410, 411, 413, 414, 415, 433–438, 452, or 453. This
criteria is similar to that set forth by Shaya et al. [28],
which adds pulmonary and venous embolism or thrombosis
(452 and 453) to the Antiplatelet Trialist Collaboration
(APTC) combined endpoint [29] to ensure that all TCEs
were captured. Code 798 (included in the APTC endpoint)
or all-cause death was omitted from the deﬁnition in order
to assess outcomes after the indexed event. Depression was
identiﬁed through at least one ICD-9 diagnostic code of
296.2, 296.3, 296.5, 296.6, 298.0, 300.4, 308.0, 309.0, 309.1,
309.4, or 311 on any claim submitted for reimbursement.
Elders were identiﬁed as having depression if the month of
therecordeddepression(1to72)waswithinsixmonthsafter
the month of a recorded TCE.
Recurrent TCEs were assessed using the same criteria set
forthfortheindexedTCE.MortalityiscapturedintheMCBS
as well as the date and source of veriﬁcation. Dates of service
utilization were then used to assign month indicators (0–
72 over the entire observation period) corresponding to the
event and used to measure time to event.
Baseline characteristics were obtained from the elder’s
survey corresponding to the year in which the indexed
TCE was identiﬁed. These variables included age, race, sex,
income, smoking history and status, height and weight,
source of ﬁrst Medicare entitlement, household living situ-
ation, and history of thrombotic event. All baseline charac-
teristics were transformed into categorical data. Income was
transformed based on Federal Poverty Level (FPL) criteria
through weighting reported income in the survey by twenty
percent due to underreporting [30], adjusting income to
2001 dollars through the use of the consumer price index
[31], and then creating a binary variable cut at $8,590
according to the 2001 FPL guidelines [32]. Body mass index
(BMI) was calculated using the elders reported height and
weight and then categorized into the following categories
indicative of frail (<25), average (25–30), and obese (>30)
elders. Isolation is known to be a risk-factor for depression
so elders were identiﬁed as living alone or not. Due to data
limitations, it was not possible to determine if the indexed
TCE was an elder’s ﬁrst, a survey question that asked “Have
you ever been told you had a myocardial infarction/heart
attack?” was assessed as a proxy for a history of a thrombotic
event.
Prescription drug use also was assessed from the survey
due to the lack of Medicare coverage for prescription drugs
during the study period. The survey included a rigorous
process of data collection that included having beneﬁciaries
save all prescription drug packages for the interviewer to
record. The beneﬁciaries were questioned about prescription
drug use regardless of the packaging in order to minimize
omitted drug use. Prescription drugs were then itemized
per patient by year and listed according to the prescrip-
tion, resulting in a list of drug events. Antidepressants
were selected from the list of prescription drug events
for elders in the year corresponding to their depression
claim. In order to assess the eﬀect of antidepressant use
on depression and maintain temporal relationships between
depression and antidepressant use, (since antidepressant
use is annually measured in the survey and depression is
measured within the ﬁrst six months following a TCE)
antidepressant use was not assessed for those elders without
a depression claim in the main analyses. However, sensi-
tivity analyses were conducted to address an independent
eﬀect.
Elders were categorized into the following categories:
(1) “SSRI users” if they had a depression claim and at
least one of the following drug events including citalopram,
ﬂuvoxamine, escitalopram, ﬂuoxetine, paroxetine, and ser-
traline; or (2) “other non-SSRI antidepressant users” if they
had a depression claim, were not previously identiﬁed as
a SSRI users, and had a drug event for any other antide-
pressant including amitriptyline, amoxapine, clomipramine,
desipramine, doxepin, imipramine, nortriptyline, protripty-
line, trimipramine, buproprion, maprotiline, mirtazapine,
nefazodone, phenelzine, tranylcypromine, trazodone, or
venlafaxine in the corresponding year of the depression
claim; and (3) “antidepressant user” if the elder had any of
the above antidepressant events listed above in the year of
the depression claim.
2.4. Analyses. Analyses included descriptive statistics, bivari-
atecomparisons(Chi-squaretestsandKaplan-Meiersurvival
plots), and multivariate statistics (Cox-proportional hazard
regression models). All statistical analyses were completed
using SAS version 9.1 (Cary, NC). Alpha was set at 0.05 a
priori for tests of signiﬁcance.
Descriptive statistics of baseline factors, recurrent events,
and mortality were conducted to display counts and per-
centages for corresponding groups and measures of central
tendency including mean, median, and standard deviation
for those elders who experienced the corresponding event.
Kaplan Meier survival plots were used to measure the time
to ﬁrst recurrent event as well as time to death by study
groups including (1) depressed and nondepressed elders;
(2) nondepressed elders, antidepressant users, and depressed
nonantidepressant users; and (3) nondepressed elders, other
antidepressant users, and SSRI users. Chi-square tests were
similarly calculated for each group.
Cox-proportional hazard models were used to measure
the time to ﬁrst recurrent TCE and time to death while
controlling for baseline characteristics. Three models were
run for each event while controlling for previous healthcare
spending, age, race, gender, smoking status and history,
poverty status, BMI, and baseline year. The primary variable
of interest in model 1 was a claim for depression, model 2
was both a claim for depression and antidepressant use by
the depressed elders, and model 3 was a claim for depression
and SSRI use by the depressed elders.
Sensitivity analyses were conducted to measure the
independent eﬀect of antidepressant use on the outcomes
and a sub-analysis was conducted to observe the eﬀect of
antidepressant use by reducing or eliminating the threat
of misclassiﬁcation bias. The sensitivity analyses included
any antidepressant use/SSRI use in the Cox-proportional
hazard models (similar to model 2 and 3) not just associated
with a depression claim. In the sub-analyses, both model 2
and 3 were repeated with the subset of patients who had
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Table 1: Sample characteristics.
#%
Total elders 7,051 100.0
Age
65–70 1,170 16.6
70–74 1,401 19.9
75–79 1,575 22.3
80+ 2,905 41.2
Race
Caucasian 6,176 87.6
African American 601 8.5
other 255 3.6
Sex
male 3,883 55.1
female 3,168 44.9
Income2
</= 100% FPL 2,969 42.1
>100% FPL 4,082 57.9
History of smoking 3,639 51.6
Current smoker 731 10.4
Body Mass Index (BMI)
<25 3,175 45.0
25–30 2,554 36.2
>30 1,213 17.2
Entitlement
disabled 94 1.3
age 6,957 98.7
Household
alone 2,417 34.3
not alone 4,634 65.7
Cohort
1997 1,623 23.0
1998 1,349 19.1
1999 1,368 19.4
2000 1,306 18.5
2001 1,406 19.9
History of acute myocardial infarction 2,174 30.8
∗The sample includes community dwelling non-HMO elders who experi-
enced a thrombotic cardiovascular event (ICD-9: 410, 411, 413, 414, 415,
433–438, 452, or 453) and had at least two years of data in the 1997 to 2002
Medicare Current Beneﬁciary Survey.
†Income adjusted to 2001 dollars and inﬂated by 20% for underreporting.
potential misclassiﬁcation bias introduced by the absence of
a depression claim for truly depressed elders.
The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agreed to the manuscript as written.
3. Results
3.1. Baseline Characteristics. Table 1 presents baseline char-
acteristics of the cohort. Elders were similarly distributed
acrossageranges,exceptforthoseaged80andolder(41.2%).
The racial/ethnic composition ofthe sample was as expected,
with Caucasian being the most prevalent (87.6%), followed
by African American (8.5%), and then other races (3.6%).
Women made up slightly less of the sample (44.9%) than
men (55.5%). Over half of the sample had a history of
smoking (51.6%) while very few reported currently smoking
(10.4%). Approximately one-third of the elders in the cohort
(30.8%) claimed to have had an AMI in the past.
3.2. Descriptive Morbidity and Mortality Rates. Of the 6,671
elders who did not have a depression claim, 67.6% had
recurrentTCEsand3.9%diedwithinoneyearoftheindexed
TCE. Of the 380 elders with a depression claim, 71.6% had
recurrent TCEs and a slightly higher mortality rate (4.7%).
Antidepressant users as a whole had a slightly higher rate
of recurrent TCEs than either of the previous groups, but a
lower mortality rate than the larger depressed group (3.9%)
Non-SSRI antidepressant users experienced a lower rate of
mortality (1.6%), which accounted for only one death. SSRI
users experienced a greater rate of recurrent TCEs compared
to non-SSRI users, 73.7% to 68.9%, respectively. Time to
recurrent event was also slightly greater for the SSRI group
compared to the non-SSRI group, with a mean time of 3.1
months compared to 2.5 months.
3.3. Unadjusted Analysis. Kaplan Meier survival plots
showed that elders with a depression claim had a recurrent
TCE sooner than other elders (Logrank P = .008). However,
there was no diﬀerence in time to death between elders
with a depression claim and those without. There also was
no diﬀerence in time to recurrent TCE or death between
any of the other subgroups of elders with a depression
claim, antidepressant user compared to nonantidepressant
userorSSRIuserscomparedwithotherantidepressantusers.
Antidepressant usersandSSRIuserswerecomparedto elders
without depression claims and no diﬀerence was found in
time to either recurrent TCE or death. Chi-square statistics
were also calculated between each group for unadjusted
comparisons of counts with similar nonsigniﬁcant ﬁndings
(Figures 1 and 2).
3.4. Multivariate Analysis. The ﬁrst model measuring the
associationbetweenadepressionclaimandtime torecurrent
TCE while controlling for key factors (previous healthcare
spending, age, race, gender, smoking status and history,
poverty status, BMI, and baseline year) revealed that the
eﬀect seen earlier in the unadjusted Kaplan Meier survival
curves between the group with a depression claim and other
elders was explained by the covariates in the model. As
a result, the hazard rate was very close to 1.00 with an
insigniﬁcantP-value.Whenaddinganyantidepressantusein
the second model, we similarly found an insigniﬁcant eﬀect
of depression claim, as well as no eﬀect by antidepressant
use.Theseresultswereidenticalwhenantidepressantusewas
replaced with SSRI use.
Similar models used to assess time to death between the
groups and antidepressant sub-groups found more move-
ment among the hazard ratios but none were statisticallyCardiology Research and Practice 5
Table 2: Recurrent events and mortality.
Nondepressed Depressed Antidepressant users SSRI users Other non-SSRI antidepressant users
#%# % # % #% #%
Total elders 6,671 100.0 380 100.0 259 100.0 198 100.0 61 100.0
Recurrent TCEs 4,510 67.6 272 71.6 188 72.6 146 73.7 42 68.9
Mortality 259 3.9 18 4.7 10 3.9 9 4.6 1 1.6
Time to ﬁrst
event (months)
mean/median/std mean/median/std mean/median/std mean/median/std mean/median/std
Recurrent TCEs 3.3/2.0/3.0 2.6/1.0/2.5 2.6/1.0/2.5 2.5/1.0/2.2 3.1/1.5/3.1
Mortality 6.9/7.0/4.1 6.1/7.0/3.8 8.5/9.0/2.8 8.3/8.0/3.0 10.0/10.0/—
∗Measures of central tendency include only those patients with an event.
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Figure 1: Time to death by group.
signiﬁcant. When antidepressant use was added into the
model, the hazard rate for a depression claim increased
to 1.52 and the hazard rate for antidepressant use showed
ap r o t e c t i v ee ﬀect at 0.52; neither ﬁnding was statistically
signiﬁcant.Similarﬁndingsresultedwhenantidepressantuse
was replaced with SSRI use in the model.
There were a few other factors in the models that
consistently showed an eﬀect on the outcomes. Those found
tosigniﬁcantlydecreasethetimetoarecurrentTCEincluded
previous healthcare spending and being male. Factors found
to signiﬁcantly decrease the time to death were previous
healthcare spending, being older than 80 years, and having
a BMI greater than or equal to 25.
Results from the sensitivity analyses reveal similar ﬁnd-
ings to those of the other models, with the exception of
any antidepressant use. It was signiﬁcantly associated with
an increase in time to death in the followup period (HR =
0.66, CI: 0.47, 0.94), however when antidepressant use was
replaced with SSRI use, this eﬀect became nonsigniﬁcant.
Neither was signiﬁcantly associated with time to recurrent
TCE. The sub-analyses of elders with only a depression
claim also revealed no eﬀect on recurrent TCE or death by
antidepressant use or SSRI use.
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Figure 2: Time to recurrent TCE by group.
4. Discussion
Neither a depression claim nor antidepressant use was found
to be associated with time to recurrent TCEs or death in
this sample of elderly Medicare beneﬁciaries. This study
indicated that a claim for depression within six months after
experiencing a TCE did not decrease time to another TCE
or death within one year in an elderly Medicare sample.
Similarly, the use of antidepressants, including this study’s
measures of any antidepressant use and SSRI-speciﬁc use,
was not associated with shorter time to recurrent TCE or
mortality within one year of the indexed TCE.
There are several key reasons why these data may
diﬀer from those of previous studies, which may include
demographic and baseline characteristics of our cohort,
measures of depression, length of followup time, and key
limitationsinherentofclaimsdataandobservationalstudies.
Baseline characteristics were similar to those expected
and without previous studies of the elderly population, they
arediﬃculttocompare.However,thisstudydidﬁndahigher
percentage of older elders (>80 years) than expected. This
was probably due to the inclusion of cerebrovascular disease
into the deﬁnition of the TCE, which deﬁned the cohort.6 Cardiology Research and Practice
Table 3: Time to event analyses.
Event Variable Hazard Ratio 95% CI P-value
Recurrent TCE
Model 1
Depression 1.09 0.96 1.23 .20
Model 2
Depression 1.07 0.86 1.33 .53
Antidepressant 1.02 0.79 1.32 .90
Model 3
Depression 1.02 0.85 1.22 .83
SSRI 1.13 0.89 1.43 .33
Model 4
Depression 1.30 1.10 1.53 >.001
Death
Model 1
Depression 1.06 0.65 1.72 .81
Model 2
Depression 1.73 0.85 3.51 .13
Antidepressant 0.52 0.21 1.33 .17
Model 3
Depression 1.27 0.65 2.47 .49
SSRI 0.83 0.33 2.10 .69
∗All four models controlled for previous healthcare spending, age, race, gender, smoking status and history, poverty status, BMI, and baseline year.
†Non-SSRI users are reference group in model 3; Nonantidepressant users are reference group in model 2.
±Ties were handled with the Exact method.
Previous studies focused primarily on associations between
depression or antidepressant use on either stroke or AMI
and not the larger group of TCEs [12, 13]. Based on
the literature [26], the link between depression and the
cardiovascular system could be assumed to aﬀect all TCEs.
However, the eﬀect may in fact depend on speciﬁc TCEs,
like AMI or stroke. This study represented elderly adults,
while most of the previous studies focused on the younger
adult population [6, 11, 16, 18]. The only factors found
to signiﬁcantly decrease the time to a recurrent TCE were
previous healthcare spending and being male; the factors
found to signiﬁcantly decrease the time to death were
previous healthcare spending, being older than 80 years, and
having a BMI greater than or equal to 25. Variables not
included in the analysis due to data limitations, but may
have been important include Killip class and Peel Index score
(clinically-deﬁned severity measures of a cardiac event) [33].
Diﬀerences in the measurement of depression may
have impacted study ﬁndings not only because diﬀerent
populations were observed, but also an eﬀect of cross-overs
due to misclassiﬁcation bias. This was evidenced by the
much lower prevalence of depression in this study (5%)
compared to previous studies reporting much higher rates
(up to 49%) [10]. Most studies use screening instruments
to assess depression rather than psychological exams; most
of which have not been validated in this population [6,
11, 16, 18]. Accurate depression measurement is critical,
as patients who suﬀer TCEs are often met with functional
restrictions that may increase the likelihood of being scored
asdepressedonanonsubjectivemeasurementtool,especially
if this assessment is done within hours or days of the
event, as is the case in most hospital-based studies [34].
The limited time from event to assessment may bias the
true estimate of the prevalence of depression since the
time requirement for a depression diagnosis may not be
observablewithoutahistoryofatleastfourteendaysafterthe
event [35]. The misclassiﬁcation bias potentially introduced
in this study would be towards null ﬁndings due to including
undiagnosed depressed elders into the nondepressed group
while maintaining a homogenous, and potentially a more
severely depressed group. This misclassiﬁcation bias may be
one reason for the null ﬁndings in this study. In an attempt
to observe misclassiﬁcation bias introduced by the depres-
sion measurement, the rate of any observed antidepressant
utilization in elders with no depression claim throughout
the survey enrollment (15%) was compared to the rate
of antidepressant utilization by elders with a depression
claim found in this study (68%). Based on the literature
providing details on the high use of antidepressants for oﬀ-
label indications and indications other than depression [36],
antidepressant use in elders without a depression claim were
probably due to other illnesses.
Due to limitations of the data, this study was unable
to account for undiagnosed and untreated depression. A
depression wash-out period prior to the indexed TCE was
not included primarily because incident depression was not
of interest. However, persistency may be one measure of
severity, and varying levels of depression severity may haveCardiology Research and Practice 7
more impact on outcomes than just evidence of depression
after the TCEs. Environmental and genetic factors are
associated with depression, as well as TCEs, but due to data
limitations, measurements of persistency and severity, and
also environment and genetics, were outside the scope of this
study.
Administrative databases and observational study
d e s i g n sa r eﬂ a w e dw i t hb i a s e ss u c ha se r r o r so nc l a i m s
submitted for payment and selection bias when measuring
drug exposure [37]. Although risk adjustment methods
were used to control for selection bias, it is diﬃcult to
reduce bias introduced by omitted variables, such as the
Killip class and Peel Index score described earlier. However,
steps were taken to include as many covariates as possible.
Also, it was impossible to determine the disease for which
the treatment was prescribed. Assumptions are generally
made in observational studies such as those in this study,
where antidepressants used by elders with depression claims
were most likely indicated for depression. The authors
acknowledge that patients could have been treated with
other drugs which may have had minor antidepressant
action, but that was outside the scope of this study.
One reason for this study’s nonsigniﬁcant ﬁndings could
be due to lack of power, however, ap r i o r ipower analysis
didprovesuﬃcientpower.Apoweranalysisconductedbased
on literature for recurrent TCEs estimated 309 nondepressed
and 103 depressed patients would be required, with a
detectable diﬀerence of 0.075, a standard deviation of 0.235,
a power of 80%, with alpha set at 0.05 [10]. Similarly
power appeared to be suﬃcient to assess mortality based on
previousﬁndings[6];withpowersetat80%,anestimated81
nondepressed and 27 depressed patients were required for a
detectable diﬀerence of 0.138, a standard deviation of 0.221
and alpha set at 0.05.
The structure of drug exposure in the MCBS limited the
ability to evaluate temporal relationships, but this limitation
will be remedied when Medicare Part D prescription drug
claims are released. Also, although the MCBS includes cross-
sectional weights for generalizing results to the population,
the design of this study prevented the use of these adjust-
ments and the cohort was analyzed as a sample which may or
may not be representative of the greater population.
While this study assumed that antidepressant use and
speciﬁcally SSRI use may have similar eﬀects on depressed
individuals suﬀe r i n gf r o mv a r i o u sT C E s ,t h i si sav e r yb r o a d
assumption that may not be accurate. In order to assess
whether a diﬀerence could be found with respect to speciﬁc
TCEs, the authors replicated the models in a subset of the
sample with AMI (N = 2,174) and found that although
depression was associate with a greater risk of recurrent TCE
(HR = 1.30,CI:1.10,1.53),inlinewiththeliterature,neither
antidepressant use nor SSRI use were associated with either
an increase or decrease in risk of recurrent TCE or death,
similarly to previous models in all TCE patients.
This was the ﬁrst study to assess the eﬀect of depression
on the risk of recurrent TCEs and mortality in a high-risk
elderly Medicare sample during the 12 months following a
TCE.Thisanalysisprovidedevidencethatdepression,treated
or untreated, was not signiﬁcantly associated with time to
recurrent TCE or death within the ﬁrst 12 months following
a TCE in this population, however in AMI only patients,
depression may be associated with recurrent events. Future
research should compare various methods of measuring
depression, including persistency and severity, and eﬀects on
speciﬁc TCEs. Prescription drug claims from the Medicare
Part D beneﬁt would enable researchers to drill down to
drug level details and provide better assessments of temporal
relationships in larger study cohorts. Although this study did
not ﬁnd depression or antidepressant use to be associated
with future events, depression screening should occur after
a TCE in elderly adults and appropriate treatment provided
and monitored.
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